Related Outside Content

Like other healthcare exchange traded funds (ETFs), dedicated pharmaceuticals ETFs are struggling this year. While prescription drug sales jumped last year and are expected to continue doing so over the next several years, rising prices for some big-name drugs have drawn the ire of politicians, leading to election year pressure on pharmaceuticals stocks and ETFs. […]

Expensive biologics have weighed on health care consumers. However, as the government tries to contain the soaring costs, a generic drugs-related exchange traded fund could capitalize on the growth of cheaper biosimilars. The Market Vectors Generic Drugs ETF (NasdaqGM: GNRX) tries to reflect the performance of the Indxx Global Generics & New Pharma Index, which […]

Slow and steady value and conservative sectors are leading market gains RPV was best performing non-leveraged ETF across various Morningstar style categories  Close behind was RZV, which like RPV, targets companies exhibiting a value characteristic Since the start of the bull market, we may come to expect growth stocks like biotechnology and technology-sector exchange traded […]

India is expanding its generic drug industry and supporting a sector-related exchange traded fund as the emerging market plays a greater role in the global health care sector. “Indian generic drugmakers have moved upwards on the global value chain and managed to gain a foothold in regulated markets such as the US and Europe,” according […]

U.S. regulators approved the sale of a lower-priced copy of an expensive blockbuster biologic drug, paving the way for further biosimilars to hit the market and supporting the outlook for the relatively new generic drugs exchange traded fund. The Market Vectors Generic Drugs ETF (NasdaqGM: GNRX) tries to reflect the performance of the Indxx Global […]

Health care investors can now target a growing segment of the pharmaceutical industry through a relatively new generics drug exchange traded fund. The Market Vectors Generic Drugs ETF (NasdaqGM: GNRX) tries to reflect the performance of the Indxx Global Generics & New Pharma Index, which tracks a number of global drug makers that generate significant […]

Breakout new drugs usually receive all the attention in the pharmaceuticals space, but generic drugs make up the bulk of the industry. Now, investors can target the rising growth in the generics space with a new sector-specific exchange traded fund. Van Eck Global’s Market Vectors Generic Drugs ETF (NasdaqGM: GNRX) began trading Wednesday, according to […]

Pharmaceuticals giant Pfizer (NYSE: PFE) is in talks to acquire specialty drugmaker Allergan (NYSE: AGN) in what may be the biggest mergers this year, adding to the consolidation activity in the health care space that has helped pharma sector exchange traded funds outperform over the past few years. People close to the Pfizer and Allergan […]

U.S. prosecutors subpoenaed Valeant Pharmaceuticals International (NYSE: VRX), reinvigorating the drug pricing drama. However, the broader pharmaceutical space and sector-related exchange traded fund were shaking off the renewed pricing scrutiny Thursday as the industry rebounded along with the markets. The U.S. Attorney’s Office in Massachusetts and another from the Manhattan U.S. Attorney’s Office sought information […]

If you’re on team Hillary Clinton in the upcoming presidential election, you might want to trim down exposure to biotechnology stocks and sector-related exchange traded funds. “Price gouging like this in the specialty drug market is outrageous. Tomorrow I’ll lay out a plan to take it on,” Democratic presidential candidate Hillary Clinton tweeted Monday, referring […]

I do the “ETF of the Week” for MarketWatch every week on Chuck Jaffe’s MoneyLife Show where I highlight big movers and disappointments among exchange traded funds. On Thursday, I highlighted the SPDR S&P Pharmaceuticals ETF (NYSEArca: XPH). The pharma sector will maintain momentum ahead on strong merger and acquisition activity. Click here to listen to […]

As the Affordable Care Act adds millions into the healthcare system, the increased demand for health products and services are supporting the momentum in healthcare-related exchange traded funds. The healthcare sector has been among the best performing area in U.S. markets, with Health Care Select Sector SPDR (NYSEArca: XLV) up 12.0% and iShares U.S. Healthcare […]

Even if the Federal Reserve begins hiking interest rates later this year, the healthcare sector, notably pharmaceutical stocks and related exchange traded funds, could outperform on greater merger and acquisition activity. Barclays analyst Douglas Tsao argues that M&A activity will continue through a rising rate environment, reports Ben Levisohn for Barron’s. “Given the importance of […]

Johnson & Johnson (NYSE: JNJ), a major component of healthcare sector exchange traded funds, will enjoy greater sales of its specialized drugs. “Based on second-quarter-to-date IMS data, we see the potential for outperformance from several of Johnson & Johnson’s key U.S. drugs–including Invokana/Invokamet [type 2 diabetes], Xarelto [blood thinner], Invega Sustenna [schizophrenia] and Remicade [Crohn’s […]

While U.S. stocks are beginning to slow, investors can still find opportunities in healthcare sector exchange traded funds. “A clear sign of strength has yet to emerge from the blurry U.S. economic picture, as uptrends in the housing and labor markets stand in contrast with consumer caution and productivity languor,” according to a BlackRock research […]

Investors may find growth opportunities in the healthcare sector and related exchange traded fund as the industry continues to develop new innovative products. For instance, U.S. healthcare conglomerate Johnson & Johnson (NYSE: JNJ) announced that in the next four years, it expects to submit over 10 new medicines, which could potentially generate $1 billion in […]

Teva Pharmaceuticals (NasdaqGS: TEVA), the largest publicly traded Israeli company, could join the already hot healthcare mergers and acquisitions race and that could prove meaningful for some pharmaceuticals exchange traded funds. “Teva has over $10 billion in debt capacity to spend on acquisitions and could go after Mylan (NYSE: MYL), which agreed to buy Abbott […]

Japanese equities are hitting new highs, and financial sector stocks and related exchange traded funds are leading the charge. Over the past month, the WisdomTree Japan Hedged Financials Fund (NYSEArca: DXJF), which tracks the Japanese financial sector and hedges against a depreciating yen currency, jumped 15.5%. In contrast, the broader non-hedged iShares MSCI Japan ETF […]

Friday is shaping up to be just another day at the office for biotechnology exchange trade funds. For second consecutive day, biotech ETFs comprise nearly all of the ETFs making new all-time highs. Today’s new all-time high club is comprised of four of the five major non-leveraged biotech ETFs, the ProShares Ultra Nasdaq Biotechnology (NasdaqGM: […]

Investors who are seeking to bolster their portfolios can include healthcare sector-specific exchange traded funds that benefit from an aging demographic, expanding services and innovative products. The healthcare sector has been among the best performing sectors so far this year. Year-to-date, the Health Care Select Sector SPDR (NYSEArca: XLV) gained 17.3% and Vanguard Health Care […]

Traditionally defensive health care stocks and sector exchange traded funds also tap into a new group of growth investment plays. Some of the best-known technology venture capitalists and prominent money managers are investing in companies that gather and analyze healthcare data, capitalizing on the potential growth in electronic record keeping and wider acceptance of personal […]

After a sharp sell-off in March and languish trading through May, the biotechnology sector and related exchange traded funds are looking to break out. The iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB), which tracks biotech and pharma stocks on the Nasdaq, fell 9.6% over the past three months, but the ETF is up 1.6% over the […]

It is not hyperbole to say 2013 was the year of the health care exchange trade fund. Multiple anecdotes prove the point. Not only was the Health Care Select Sector SPDR (NYSEArca: XLV) the second-best of the nine sector SPDRs, but four biotechnology funds were among 2013’s 10 best non-leveraged ETFs. The strength has carried […]

The health care industry, along with related exchange traded funds, was salivating at the untapped revenue President Obama’s Affordable Care Act would bring in, but potential enrollment problems could lead to a 30% cut in U.S. pharma sales projections. According to the IMS Institute, U.S. prescription drug sales could fall as low as $320 billion […]

Congress is working on reform legislation in the pharmaceutical industry to stomp out copycat drug makers, lifting large pharmaceutical stocks and related exchange traded funds. The SPDR S&P Pharmaceuticals ETF (NYSEArca: XPH) was the best performing non-leveraged ETF over the past week, gaining 9.2%. XPH is up 55.1% year-to-date. On Tuesday, the Senate voted 97 […]

Biotechnology ETFs, a leadership group for all of this year, succumbed to selling pressure this earlier this  week,  but the same cannot be said of all health care ETFs. Investors may be showing a preference more conservative fare when it comes to health care ETFs. The $524 million SPDR S&P Pharmaceuticals ETF (NYSE: XPH) confirms […]

Riding out tax hikes, interest rate risk and geopolitical tensions, the broad equity markets touched historic highs this year, with alternative energy, biotech and technology stock exchange traded funds leading the pack. In the technology space, social media stocks are experiencing robust gains on increased global connectivity, especially in the emerging markets where internet use […]

Stocks as an asset class have shrugged off a wide variety of risks throughout the year. Sequestration failed to derail equity enthusiasm. The May-June interest rate spike did little to deter dip-buyers. And I suspect that any actual downside for the markets in October, whether caused by political strife or disappointing economic data, will ultimately […]

I do the “ETF of the Week” for MarketWatch every Thursday on Chuck Jaffe’s MoneyLife Show where I highlight big movers and disappointments within the exchange traded fund market. This Thursday, I took a look at the SPDR S&P Biotech ETF (NYSEArca: XBI). Instead of betting on a few small up-and-coming biotechnology firms, this equal-weight […]

Rummaging through small-cap biotechnology companies, investors can pick out the next break-through drug provider, but it also leaves you exposed to potential flubs. Instead, exchange traded funds offer diversified basket to the growing sector. “The jarring pace of change, single-product liability, regulatory uncertainties, and intellectual property rights make picking stocks in the biotech sector a […]